News
Talecris responds to FTC, defends acquisition by CSL as "pro-competitive"
RESEARCH TRIANGLE PARK, NC – (Business Wire) Talecris Biotherapeutics, Inc., has issued a response the to Federal Trade Commission’s announcement that the FTC would file an administrative complaint challenging CSL’s proposed acquisition of Talecris and a complaint in US Federal District Court to enjoin the transaction.
In response, Lawrence D. Stern, Talecris’ Chairman and CEO, said, “We continue to believe that this transaction is pro-competitive for our industry and in the best interests of our patients, customers, employees, sponsors, and lenders. The combination of CSL and Talecris would materially increase IGIV capacity in the next several years.”
